Erasca flagged updated Phase 1 AURORAS-1 monotherapy results for ERAS-0015 for future presentation at the ENA Symposium on Nov. 20.
The company pointed to clinical activity with favorable tolerability in earlier disclosures, positioning the expanded dataset as a key near-term catalyst.
Nonclinical combination findings for ERAS-0015 with ERAS-4001 will also be presented, highlighting synergistic effects in KRAS G12X-driven models.
Management framed the readouts as supporting plans to move ERAS-0015 toward three potentially registration-enabling trials in pancreatic cancer and lung cancer.
ERAS•
